Johns Hopkins Center for Vascular Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
VESS16 - Trends in Rivaroxaban Use for Symptomatic Peripheral Artery Disease Before and After FDA Approval
Wednesday, June 10, 20263:57 PM - 4:05 PM ET